Compare HUBC & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUBC | GRI |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | Israel | United States |
| Employees | 322 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.3M |
| IPO Year | N/A | 2020 |
| Metric | HUBC | GRI |
|---|---|---|
| Price | $0.09 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | ★ 12.1M | 32.1K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $0.18 |
| 52 Week High | $5.09 | $6.70 |
| Indicator | HUBC | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 24.79 | 48.90 |
| Support Level | N/A | $2.18 |
| Resistance Level | $0.50 | $2.66 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 6.15 | 41.73 |
Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.